The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) is a huge mover today! About 218,523 shares traded hands. Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has risen 125.98% since March 3, 2016 and is uptrending. It has outperformed by 117.64% the S&P500.
The move comes after 9 months negative chart setup for the $176.46 million company. It was reported on Oct, 6 by Barchart.com. We have $11.40 PT which if reached, will make NASDAQ:SMMT worth $24.70 million less.
Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Ratings Coverage
Out of 3 analysts covering Summit Therapeutic (NASDAQ:SMMT), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Summit Therapeutic has been the topic of 4 analyst reports since August 19, 2015 according to StockzIntelligence Inc. The rating was maintained by Oppenheimer on Wednesday, August 19 with “Buy”. The stock of Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) has “Buy” rating given on Friday, September 16 by H.C. Wainwright. The firm earned “Hold” rating on Tuesday, September 1 by Zacks. On Tuesday, June 21 the stock rating was initiated by Janney Capital with “Buy”.
According to Zacks Investment Research, “Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.”
More notable recent Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) news were published by: Marketwatch.com which released: “Summit Therapeutics PLC ADR” on April 22, 2011, also Nasdaq.com with their article: “Mid-Afternoon Market Update: Dow Drops More Than 100 Points; Summit …” published on October 04, 2016, Schaeffersresearch.com published: “Biotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV” on September 26, 2016. More interesting news about Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 13, 2011 as well as Businessfinancenews.com‘s news article titled: “Summit Therapeutics Receives Phase 2 Trial Approval for DMD Patients” with publication date: January 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.